10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
A new California, USA-based biotechnology company, named Septerna, has launched today with the aim of discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs). 27 January 2022
US biotech Vertex Pharmaceuticals has reported full-year product revenues of $7.57 billion for 2021, a 22% increase compared to 2020, while adjusted earnings were 26% higher at $13.02. 27 January 2022
T-cell immunotherapy developer Atara Biotherapeutics has entered into a long-term strategic agreement with Fujifilm Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire Atara’s T-Cell operations and manufacturing (ATOM) facility in Thousand Oaks, California for $100 million upfront, retaining current manufacturing and quality staff at the site. 27 January 2022
US biotech firm Orgenesis today announces it has achieved its latest milestone in the second phase of its collaboration with the Hospital Infantil Universitario Nino Jesus (Hospital) in Madrid, Spain. 27 January 2022
Calling MIG a leading German venture capital (VC) investment firm and one with a focus on life sciences and deep tech companies, might not do justice to the key role that it is playing in advancing some of Europe’s most promising biotech start-ups. 27 January 2022
A 30% drop in the share price of Alzheimer’s specialist Cortexyme has followed news of an abrupt change to its clinical research priorities. 27 January 2022
Replacing its retiring co-founder and chief executive Onno van de Stolpe, Belgium-based biotech Galapagos today announced that industry veteran Paul Stoffels will join the company as CEO effective April 1. 27 January 2022
Swiss pharma giant Roche recently announced that it will initiate a new Phase II trial to reassess its pipeline antisense therapy, tominersen, in the treatment of Huntington's disease (HD). 27 January 2022
America traded shares of Immunocore Holdings were up 3.2% at $22.62 mid-morning, having hit $24.06 in earlier activity, after the UK biotech announced approval from the US Food and Drug Administration of Kimmtrak (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM). 26 January 2022
In another example of the growing popularity of the SPAC merger, digital medicine company Akili Interactive is to list on the Nasdaq in this way, with the deal expected to close in mid-2022. 26 January 2022
Russia plans to begin the production of a scarce drug based on ethosuximide for the treatment of epilepsy, according to recent statements by some of local analysts in the field of pharmaceutics and Russian media, reports The Pharma Letter’s local correspondent. 26 January 2022
US autoimmune drug developer Kyverna Therapeutics today announced it has closed an oversubscribed $85 million Series B financing round led by Northpond Ventures. 26 January 2022
Potentially curative gene therapies are among a number of exciting new sickle cell disease (SCD) drugs set to hit the US market, according to data and analytics company GlobalData. 26 January 2022
US biopharma firm Sierra Oncology yesterday announced positive top-line data from the pivotal Phase III MOMENTUM study - a global, randomized, double-blind clinical trial evaluating momelotinib (MMB) in myelofibrosis patients who are symptomatic and anemic and previously treated with an approved JAK inhibitor. 26 January 2022
Swiss contract development and manufacturing organization (CDMO) Lonza has reported full-year 2021 sales of 5.4 billion francs ($5.9 billion). 26 January 2022
Delaware’s Incyte, a developer of novel therapies to address serious unmet medical need, has stopped working on the small molecule parsaclisib and the novel antibody MCLA-145. 26 January 2022
Swedish immuno-oncology firm BioInvent, the first company to discover two innovative new cancer antibody targets, is fully funded to develop antibodies across five clinical projects over the coming three to four years. 26 January 2022
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in the USA, the first generic to its reference medicine to be approved by the US Food and Drug Administration (FDA). 11 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of the Quarterly Biosimilar Market Report in the United States. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024